Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1254


A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols.

Lundberg K, Roos AK, Pavlenko M, Leder C, Wehrum D, Guevara-PatiƱo J, Andersen RS, Pisa P.

Vaccine. 2009 Mar 4;27(10):1557-65. doi: 10.1016/j.vaccine.2009.01.011. Epub 2009 Jan 24.


Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation.

Chakraborty NG, Stevens RL, Mehrotra S, Laska E, Taxel P, Sporn JR, Schauer P, Albertsen PC.

Cancer Immunol Immunother. 2003 Aug;52(8):497-505. Epub 2003 Jun 3.


Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen.

Terasawa H, Tsang KY, Gulley J, Arlen P, Schlom J.

Clin Cancer Res. 2002 Jan;8(1):41-53.


Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide.

Correale P, Walmsley K, Zaremba S, Zhu M, Schlom J, Tsang KY.

J Immunol. 1998 Sep 15;161(6):3186-94.


In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen.

Correale P, Walmsley K, Nieroda C, Zaremba S, Zhu M, Schlom J, Tsang KY.

J Natl Cancer Inst. 1997 Feb 19;89(4):293-300.


Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide.

Perambakam S, Hallmeyer S, Reddy S, Mahmud N, Bressler L, DeChristopher P, Mahmud D, Nunez R, Sosman JA, Peace DJ.

Cancer Immunol Immunother. 2006 Sep;55(9):1033-42. Epub 2005 Nov 10.


Identification of an immunodominant H-2D(b)-restricted CTL epitope of human PSA.

Pavlenko M, Leder C, Roos AK, Levitsky V, Pisa P.

Prostate. 2005 Jun 15;64(1):50-9.


Depletion of CD25+ cells from human T-cell enriched fraction eliminates immunodominance during priming with dendritic cells genetically modified to express a secreted protein.

Mincheff M, Zoubak S, Altankova I, Tchakarov S, Pogribnyy P, Makogonenko Y, Botev C, Meryman HT.

Cancer Gene Ther. 2005 Feb;12(2):185-97.


Identification of HLA-DRB1*1501-restricted T-cell epitopes from prostate-specific antigen.

Klyushnenkova EN, Link J, Oberle WT, Kodak J, Rich C, Vandenbark AA, Alexander RB.

Clin Cancer Res. 2005 Apr 15;11(8):2853-61.


A cytomegalovirus-based vaccine expressing a single tumor-specific CD8+ T-cell epitope delays tumor growth in a murine model of prostate cancer.

Klyushnenkova EN, Kouiavskaia DV, Parkins CJ, Caposio P, Botto S, Alexander RB, Jarvis MA.

J Immunother. 2012 Jun;35(5):390-9. doi: 10.1097/CJI.0b013e3182585d50.


Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro.

Heiser A, Dahm P, Yancey DR, Maurice MA, Boczkowski D, Nair SK, Gilboa E, Vieweg J.

J Immunol. 2000 May 15;164(10):5508-14.


Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.

Horiguchi Y, Nukaya I, Okazawa K, Kawashima I, Fikes J, Sette A, Tachibana M, Takesako K, Murai M.

Clin Cancer Res. 2002 Dec;8(12):3885-92.


Efficient transfer of PSA and PSMA cDNAs into DCs generates antibody and T cell antitumor responses in vivo.

Medin JA, Liang SB, Hou JW, Kelley LS, Peace DJ, Fowler DH.

Cancer Gene Ther. 2005 Jun;12(6):540-51.


Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors.

Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD, Dahm P, Niedzwiecki D, Gilboa E, Vieweg J.

J Clin Invest. 2002 Feb;109(3):409-17.


Human CTLs to wild-type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells.

Oh S, Terabe M, Pendleton CD, Bhattacharyya A, Bera TK, Epel M, Reiter Y, Phillips J, Linehan WM, Kasten-Sportes C, Pastan I, Berzofsky JA.

Cancer Res. 2004 Apr 1;64(7):2610-8.


Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.

Karan D, Dubey S, Van Veldhuizen P, Holzbeierlein JM, Tawfik O, Thrasher JB.

Immunotherapy. 2011 Jun;3(6):735-46. doi: 10.2217/imt.11.59.


Immune monitoring in a phase 1 trial of a PSA DNA vaccine in patients with hormone-refractory prostate cancer.

Miller AM, Ozenci V, Kiessling R, Pisa P.

J Immunother. 2005 Jul-Aug;28(4):389-95.


Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1.

Li N, Qin H, Li X, Zhou C, Wang D, Ma W, Lin C, Zhang Y, Wang S, Zhang S.

J Clin Immunol. 2007 Jan;27(1):117-30. Epub 2006 Dec 16.

Items per page

Supplemental Content

Write to the Help Desk